Table 1.
Method | Advantages | Disadvantages | Application |
---|---|---|---|
MTT, MTS, XTT, WST-1 |
Inexpensive; Highly accessible; Relatively fast; Simple in execution. |
Does not detect dead cells; Cells are analyzed in bulk; Additional steps in protocol may increase data variability (in case of MTT); Toxic to cells. |
High-throughput screening |
LIVE/DEAD assay |
Allows to evaluate numbers of both viable and dead cells; Rapid process; Simple in execution; Moderately accessible; Can be optimized for microscopic studies. |
Expensive; Cells are analyzed in bulk; Requires optimization for each cell line; Limited sensitivity in adherent cells [52]. |
Screening of small compound collections |
Annexin V flow cytometry analysis |
Estimates the fractions of viable cells, cells in early apoptosis, and cells in late apoptosis/necrosis; Analyzes individual cells. |
Provides no information on total cell number; Does not discern between cells in late apoptosis and necrosis. Analysis of adherent cells requires additional procedures that may affect the viability; Cannot be scaled for high-throughput analysis. |
Study of apoptosis in a limited number of samples; Identification of drug-sensitive and drug-resistant subpopulations. |
Western blotting |
Allows to estimate molecular mechanisms of drug action; High sensitivity. |
Provides no information on cell numbers; Cells are analyzed in bulk; Requires high-quality antibodies against cell death markers; Cannot be scaled for high-throughput analysis. |
Study of molecular mechanisms of drug action in a small number of samples. |